Vascular Endothelial Growth Factor Receptor Expression in Orbital Cavernous Malformations and Lymphatic Malformations.

Ophthalmology and vision care Pub Date : 2021-01-01 Epub Date: 2021-03-31

Ann Q Tran, Marissa K Shoji, Alexandra Levitt, Wendy W Lee

{"title":"Vascular Endothelial Growth Factor Receptor Expression in Orbital Cavernous Malformations and Lymphatic Malformations.","authors":"Ann Q Tran, Marissa K Shoji, Alexandra Levitt, Wendy W Lee","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the presence of vascular endothelial growth factor receptors (VEGFR) in orbital cavernous malformations and lymphatic malformations to further understand the feasibility of anti-VEGF treatment.Methods: This study was a single-center retrospective chart review performed at the Bascom Palmer Eye Institute of patients who underwent surgical excision of orbital cavernous malformations and lymphangiomas from 2000 - 2017. Immunohistochemical staining of these lesions for VEGFR1 and VEGFR2 expression was performed.Results: A total of 25 patients were identified with cavernous malformations (n=15) and lymphatic malformations (n=10). Ten specimens (7 cavernous malformations, 3 lymphatic malformations) underwent further immunohistochemical analysis. Six of 7 cavernous malformations and one of 3 lymphatic malformations stained positive for VEGFR1 and VEGFR2.Conclusions: Both cavernous malformations and lymphatic malformations appear to express VEGFR with varying frequency. Additional studies are needed to better characterize the pathogenesis of these lesions, nature of VEGFR expression, and potential efficacy of anti-VEGF treatment.","PeriodicalId":93347,"journal":{"name":"Ophthalmology and vision care","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297820/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology and vision care","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/31 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To investigate the presence of vascular endothelial growth factor receptors (VEGFR) in orbital cavernous malformations and lymphatic malformations to further understand the feasibility of anti-VEGF treatment.

Methods: This study was a single-center retrospective chart review performed at the Bascom Palmer Eye Institute of patients who underwent surgical excision of orbital cavernous malformations and lymphangiomas from 2000 - 2017. Immunohistochemical staining of these lesions for VEGFR1 and VEGFR2 expression was performed.

Results: A total of 25 patients were identified with cavernous malformations (n=15) and lymphatic malformations (n=10). Ten specimens (7 cavernous malformations, 3 lymphatic malformations) underwent further immunohistochemical analysis. Six of 7 cavernous malformations and one of 3 lymphatic malformations stained positive for VEGFR1 and VEGFR2.

Conclusions: Both cavernous malformations and lymphatic malformations appear to express VEGFR with varying frequency. Additional studies are needed to better characterize the pathogenesis of these lesions, nature of VEGFR expression, and potential efficacy of anti-VEGF treatment.

Abstract Image

本刊更多论文

血管内皮生长因子受体在眶海绵状血管瘤和淋巴管畸形中的表达。

目的:探讨血管内皮生长因子受体(vascular endothelial growth factor receptor, VEGFR)在眶海绵状血管瘤和淋巴管畸形中的存在，进一步了解抗vegf治疗的可行性。方法:本研究是一项在巴斯科姆帕尔默眼科研究所进行的单中心回顾性图表回顾，研究对象是2000年至2017年接受手术切除的眶海绵状畸形和淋巴管瘤患者。对这些病变进行VEGFR1和VEGFR2表达的免疫组织化学染色。结果:共25例患者被鉴定为海绵体畸形(n=15)和淋巴畸形(n=10)。10例(海绵状畸形7例，淋巴畸形3例)进一步进行免疫组化分析。7例海绵样畸形中有6例，3例淋巴样畸形中有1例VEGFR1和VEGFR2染色阳性。结论:海绵体畸形和淋巴畸形均表现出不同频率的VEGFR表达。需要进一步的研究来更好地描述这些病变的发病机制、VEGFR表达的性质以及抗vegf治疗的潜在疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmology and vision care

自引率

0.00%

发文量